Effects of acidic fibroblast growth factor on cholinergic neurons of nucleus basalis magnocellularis and in a spatial memory task following cortical devascularization.
The ability of acidic fibroblast growth factor to elicit a trophic response in the nervous system of the rat was tested in vitro and in vivo. Treatment of cultured septal cells with acidic fibroblast growth factor resulted in an elongation of glial processes as assessed by immunostaining for glial fibrillary acidic protein. Increased choline acetyltransferase was also observed. The responses to acidic fibroblast growth factor in vivo were studied in rats trained in a spatial memory task, using the Morris water maze. Randomly selected animals were subjected to unilateral cortical devascularization. This lesion results in partial unilateral infarction of the neocortex, and in retrograde degeneration of the nucleus basalis magnocellularis. Animals were tested post-lesion for memory retention and were then killed for morphological studies. Intracerebroventricular administration of acidic fibroblast growth factor (0.6 microgram/h for seven days starting at surgery) prevented the lesion-induced impairment in this test, and reduced the nucleus basalis magnocellularis cholinergic degeneration, as assessed by morphometric choline acetyltransferase-like immunoreactivity and radioenzymatic assay for choline acetyltransferase activity. The preservation of the phenotype of injured cholinergic neurons of the nucleus basalis magnocellularis by acidic fibroblast growth factor was indicated by the maintenance of the cross-sectional area of cell bodies and mean length of neuritic processes one month after surgery. The effect of acidic fibroblast growth factor in non-cholinergic cells remains to be investigated. It is suggested that acidic fibroblast growth factor may alleviate the lesion-induced deficit in the memory retention task by preventing disruption of functional connections between nucleus basalis magnocellularis and intact cortical areas.(ABSTRACT TRUNCATED AT 250 WORDS)
Figueiredo
B C
BC
Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.
Piccardo
P
P
Maysinger
D
D
Clarke
P B
PB
Cuello
A C
AC
D000818:Animals; D002478:Cells, Cultured; D002544:Cerebral Infarction / Q000188:drug therapy / Q000503:physiopathology*; D002795:Choline O-Acetyltransferase / Q000096:biosynthesis*; D002799:Cholinergic Fibers / Q000187:drug effects / Q000502:physiology; D016220:Fibroblast Growth Factor 1 / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D008568:Memory / Q000502:physiology*; D011939:Mental Recall / Q000502:physiology; D009419:Nerve Tissue Proteins / Q000096:biosynthesis*; D009474:Neurons / Q000187:drug effects*; D011597:Psychomotor Performance / Q000187:drug effects / Q000502:physiology; D051381:Rats; D012183:Retrograde Degeneration; D013037:Spatial Behavior; D013377:Substantia Innominata / Q000187:drug effects* / Q000503:physiopathology
D009419:Nerve Tissue Proteins; D016220:Fibroblast Growth Factor 1; D002795:Choline O-Acetyltransferase